非酒精性脂肪性肝炎的诊断与监测:现状与未来方向
非酒精性脂肪性肝病全球患病率为25%,非酒精性脂肪性肝炎是其炎症亚型,与疾病进展、肝硬化和死亡率升高相关。肝活检是当前诊断和纤维化分期的标准,但为有创、昂贵且不能纵向监测。本文综述了可用于评估肝脂肪变和纤维化严重程度的最相关影像生物标志物及其在非酒精性脂肪性肝病患者中的应用。
要点
- 非酒精性脂肪性肝病全球患病率为25%,非酒精性脂肪性肝炎是其炎症亚型。
- 肝活检是当前诊断和纤维化分期的标准,但有创、昂贵且不能纵向监测。
- 已提出多种无创定量影像生物标志物可评估肝脂肪变和纤维化严重程度。
核心结论
- 非酒精性脂肪性肝炎的无创诊断和准确风险分层仍是未满足的临床需求。
研究设计与样本
- 综述,检索并汇总了可用于评估非酒精性脂肪性肝病患者肝脂肪变和纤维化严重程度的最相关影像生物标志物。
局限性
- 肝活检为有创、昂贵且不能用于纵向监测。
- 非酒精性脂肪性肝炎的无创诊断和准确风险分层仍是未满足的需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Nonalcoholic fatty liver disease (NAFLD) is a common liver disease, with a worldwide prevalence of 25%. NAFLD is a spectrum that includes nonalcoholic fatty liver defined histologically by isolated hepatocytes steatosis without inflammation and nonalcoholic steatohepatitis (NASH) is the inflammatory subtype of NAFLD and is associated with disease progression, development of cirrhosis, and increased rates of liver-specific and overall mortality. The differentiation between NAFLD and NASH as well as staging NASH are important yet challenging clinical problems. Liver biopsy is currently the standard for disease diagnosis and fibrosis staging. However, this procedure is invasive, costly, and cannot be used for longitudinal monitoring. Therefore, several noninvasive quantitative imaging biomarkers have been proposed that can estimate the severity of hepatic steatosis and fibrosis. Despite this, noninvasive diagnosis of NASH and accurate risk stratification remain unmet needs. In this work, the most relevant available imaging biomarkers are reviewed and their application in patients with NAFLD are discussed.
引用
- Kadi D, Loomba R, Bashir MR, et al. Diagnosis and Monitoring of Nonalcoholic Steatohepatitis: Current State and Future Directions. Radiology. 2024. PMID: 38226882. doi:10.1148/radiol.222695
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。